Press Releases

Gilead Sciences Announces Acceptance of Viread Late Breaker Abstracts At Upcoming 14th International AIDS Conference

- Forty-eight Week Data Evaluating Viread(TM) in Treatment-naive Patients, Pharmacokinetic Data from Study of Viread and Didanosine to be Presented -

Clinical investigator Schlomo Staszewski, MD, University Hospital, J.W. Goethe-Universitat, Frankfurt, Germany, will present 48-week safety and efficacy data from Study 903 of Viread (Abstract #LbOr17). This study was designed to compare the efficacy and safety of a treatment regimen of Viread, lamivudine (3TC) and efavirenz to a regimen of stavudine (d4T), lamivudine and efavirenz in 600 antiretroviral-naive HIV patients. Study 903 will be presented on Friday, July 12 during the Late Breaker Session between 8:30 a.m. and 10:00 a.m. Preliminary results from this study were summarized in a press release issued on May 7, 2002. In addition, Andrew Cheng, MD, PhD, Gilead Sciences, will present data from Study 932, which evaluated the pharmacokinetic interactions of didanosine EC and Viread when co-administered in 28 individuals for a duration of 15 days. Study 932 (Abstract #LbPeB9026) will be presented as a poster on Thursday, July 11 from 12:00 p.m.- 2:00 p.m.

Viread will be the subject of an additional 12 posters or presentations during the International AIDS Conference. A schedule of presentations may be obtained from the International AIDS Conference Web site at Late breaker abstracts will be made available to conference participants upon registration at the meeting and will be available from Gilead upon request.

    About Gilead Sciences

    For complete prescribing information, please visit
    Note to Editors: Viread is a trademark of Gilead Sciences, Inc.

CONTACT:          Gilead Sciences
                  Susan Hubbard, 650/522-5715 (Investors)
                  Amy Flood, 650/522-5643 (Media)

Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire.  All rights reserved.